MannKind Corp
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
ASX data centre share forecasts AI fuelled earnings surge
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.90 | 6.40 | 0.07% |
| CAC 40 | 8,334.50 | 66.68 | -0.79% |
| DAX 40 | 26,258.11 | 311.88 | -1.17% |
| Dow JONES (US) | 53,185.90 | 374.09 | -0.70% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,566.99 | 17.80 | -0.07% |
| NASDAQ | 26,370.89 | 31.54 | -0.12% |
| Nikkei 225 | 66,374.00 | 62.07 | 0.09% |
| NZX 50 Index | 13,770.64 | 146.66 | -1.05% |
| S&P 500 | 7,686.14 | 25.62 | -0.33% |
| S&P/ASX 200 | 9,037.30 | 12.30 | 0.14% |
| SSE Composite Index | 3,986.10 | 0.20 | -0.01% |